NASDAQ: LSTALisata Therapeutics Inc Stock
$3.56+0.08 (+2.3%)
Updated Jun 12, 2026
LSTA Price
$3.56
Fair Value Price
$1.86
Market Cap
$32.42M
52 Week Low
$1.81
52 Week High
$5.07
P/E
-1.91x
P/B
2.97x
P/S
265.36x
PEG
N/A
Dividend Yield
N/A
Revenue
$170.00k
Earnings
-$16.35M
Gross Margin
100%
Operating Margin
-9,845.88%
Profit Margin
-9,618.2%
Debt to Equity
0.31
Operating Cash Flow
-$14M
Beta
0.71
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
LSTA Overview
Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on pioneering and bringing to market cellular therapies. These treatments are designed to either reverse disease progression or facilitate the repair of damaged bodily tissues. The company's product portfolio features several notable candidates: HONEDRA, which has received SAKIGAKE designation and is presently in Phase II clinical trials for critical limb ischemia; XOWNA, currently undergoing Phase IIb testing for coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy aimed at individuals with chronic kidney disease who are not yet on dialysis. Founded in 1980 and based in Basking Ridge, New Jersey, the company was initially known as NeoStem, Inc., then rebranded as Caladrius Biosciences, Inc. in June 2015, before assuming its present identity as Lisata Therapeutics, Inc. on September 15, 2022.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine LSTA's potential to beat the market
- LSTA doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
LSTA
RankedUnranked of 463
RankedUnranked of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $230.56 | A | |
| $53.13 | A | |
| $15.82 | A |
Be the first to know about important LSTA news, forecast changes, insider trades & much more!
LSTA News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how LSTA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LSTA ($3.56) is overvalued by 91.85% relative to our estimate of its Fair Value price of $1.86 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
LSTA ($3.56) is not significantly undervalued (91.85%) relative to our estimate of its Fair Value price of $1.86 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
LSTA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more LSTA due diligence checks available for Premium users.
Valuation
LSTA fair value
Fair Value of LSTA stock based on Discounted Cash Flow (DCF)
Price
$3.56
Fair Value
$1.86
Overvalued by
91.85%
LSTA ($3.56) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
LSTA ($3.56) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
LSTA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
LSTA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.91x
Industry
16.53x
Market
14.15x
LSTA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.97x
Industry
4.85x
LSTA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
LSTA's financial health
Profit margin
Revenue
$0.0
Net Income
-$4.5M
Profit Margin
0%
LSTA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
LSTA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$14.1M
Liabilities
$3.4M
Debt to equity
0.31
LSTA's short-term assets ($14.02M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LSTA's short-term assets ($14.02M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LSTA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
LSTA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.1M
Investing
$0.0
Financing
$181.0k
LSTA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
LSTA vs Biotech Stocks
Lisata Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.